Status:
COMPLETED
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
Lead Sponsor:
Amgen
Conditions:
Gynecological Malignancies
Genital Neoplasms, Female
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in gynecological cancer patients treated with darbepoetin alfa or recombinant human erythrop...
Eligibility Criteria
Inclusion
- Subjects receiving multi-cycle chemotherapy for gynecological cancer - Anemia due to chemotherapy (hgb less than or equal to 11.0 g/dL) - Expected to receive greater than or equal to 8 additional weeks of chemotherapy as part of their planned treatment - Karnofsky Performance Scale (KPS) greater than or equal to 50% - Adequate renal function - Adequate liver function
Exclusion
- Iron deficiency - Known positive test for human immunodeficiency virus (HIV) infection
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2003
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00121030
Start Date
October 1 2002
End Date
December 1 2003
Last Update
December 24 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.